Trial comes too late as psychiatric side effects end hope for rimonabant.
Stapleton
John A
JA
Health Behaviour Research Centre, Department of Epidemiology and Public Health, University College London, London, UK. j.stapleton@ucl.ac.uk
D000279:Administration, Cutaneous; D001290:Attitude; D006801:Humans; D010880:Piperidines / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors*; D000077285:Rimonabant; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation
D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D000077285:Rimonabant